Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $145
Barclays analyst Etzer Darout maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and raises the price target from $128 to $145.
Stocks · News reference
Monopar Therapeutics Begins Rolling Submission Of FDA New Drug Application For ALXN1840 Albumin Tripartite Complex Activator To Treat Wilson Disease
The FDA has authorized Monopar to submit the NDA on a rolling basis, allowing completed sections of the application to be submitted and reviewed while the Company finalizes the remaining sections. Monopar has submitted
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
This Stubhub Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. STUB downgraded, MNPR neutral, BETR.
Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $128
Barclays analyst Etzer Darout maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and raises the price target from $125 to $128.
Cantor Fitzgerald Downgrades Monopar Therapeutics to Neutral, Raises Price Target to $119
Cantor Fitzgerald analyst Kristen Kluska downgrades Monopar Therapeutics (NASDAQ:MNPR) from Overweight to Neutral and raises the price target from $109 to $119.